Product Code: TMRGL84899
Scope of Report
The report provides revenue of the global chronic kidney disease nutritional supplement market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global chronic kidney disease nutritional supplement market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the chronic kidney disease nutritional supplement market.
The report delves into the competitive landscape of the global chronic kidney disease nutritional supplement market. Key players operating in the global chronic kidney disease nutritional supplement market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global chronic kidney disease nutritional supplement market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Chronic Kidney Disease Nutritional Supplement Market
4. Market Overview
- 4.1. Overview
- 4.2. Market Dynamics
- 4.2.1. Drivers
- 4.2.2. Restraints
- 4.2.3. Opportunities
- 4.3. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, 2017-2031
5. Key Insights
- 5.1. Average Pricing Per Nutrition Type
- 5.2. Porter's Five Force Analysis
- 5.3. COVID-19 Impact Analysis
- 5.4. Prevalence of Chronic Kidney Diseases Globally
6. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Nutrition Type
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Nutrition Type, 2017-2031
- 6.3.1. Amino Acid Supplements
- 6.3.1.1. Alpha-Ketoanalogue Supplements
- 6.3.1.2. Alpha Lipoic Acid Supplements
- 6.3.1.3. Others
- 6.3.2. Vitamin & Mineral Supplements
- 6.3.3. Probiotics
- 6.3.4. Prebiotics/Fibers
- 6.3.5. Others
- 6.4. Market Attractiveness Analysis, by Nutrition Type
7. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Dosage Form
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Dosage Form, 2017-2031
- 7.3.1. Capsule Form
- 7.3.2. Liquid Form
- 7.3.3. Powder Form
- 7.3.4. Others
- 7.4. Market Attractiveness Analysis, by Dosage Form
8. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by FSMP Mode of Administration
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by FSMP Mode of Administration, 2017-2031
- 8.3.1. Oral Nutrition (ON)
- 8.3.2. Enteral Nutrition (EN)
- 8.4. Market Attractiveness Analysis, by FSMP Mode of Administration
9. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by CKD Stage
- 9.1. Introduction & Definition
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast, by CKD Stage, 2017-2031
- 9.3.1. Pre-dialysis Stage 1-2
- 9.3.2. Pre-dialysis Stage 3-5
- 9.3.3. Dialysis
- 9.3.4. End-stage Renal Disease
- 9.4. Market Attractiveness Analysis, by CKD Stage
10. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Distribution Channel
- 10.1. Introduction & Definition
- 10.2. Key Findings/Developments
- 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Stores
- 10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast, by Region
- 11.1. Key Findings
- 11.2. Market Value Forecast, by Region
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
- 11.3. Market Attractiveness Analysis, by Region
12. North America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Nutrition Type, 2017-2031
- 12.2.1. Amino Acid Supplements
- 12.2.1.1. Alpha-Ketoanalogue Supplements
- 12.2.1.2. Alpha Lipoic Acid Supplements
- 12.2.1.3. Others
- 12.2.2. Vitamin & Mineral Supplements
- 12.2.3. Probiotics
- 12.2.4. Prebiotics/Fibers
- 12.2.5. Others
- 12.3. Market Value Forecast, by Dosage Form, 2017-2031
- 12.3.1. Capsule Form
- 12.3.2. Liquid Form
- 12.3.3. Powder Form
- 12.3.4. Others
- 12.4. Market Value Forecast, by FSMP Mode of Administration, 2017-2031
- 12.4.1. Oral Nutrition (ON)
- 12.4.2. Enteral Nutrition (EN)
- 12.5. Market Value Forecast, by CKD Stage, 2017-2031
- 12.5.1. Pre-dialysis Stage 1-2
- 12.5.2. Pre-dialysis Stage 3-5
- 12.5.3. Dialysis
- 12.5.4. End-stage Renal Disease
- 12.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.6.1. Hospital Pharmacies
- 12.6.2. Retail Pharmacies
- 12.6.3. Online Stores
- 12.7. Market Value Forecast, by Country, 2017-2031
- 12.7.1. U.S.
- 12.7.2. Canada
- 12.8. Market Attractiveness Analysis
- 12.8.1. By Nutrition Type
- 12.8.2. By Dosage Form
- 12.8.3. By FSMP Mode of Administration
- 12.8.4. By CKD stage
- 12.8.5. By Distribution Channel
- 12.8.6. By Country
13. Europe Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Nutrition Type, 2017-2031
- 13.2.1. Amino Acid Supplements
- 13.2.1.1. Alpha-Ketoanalogue Supplements
- 13.2.1.2. Alpha Lipoic Acid Supplements
- 13.2.1.3. Others
- 13.2.2. Vitamin & Mineral Supplements
- 13.2.3. Probiotics
- 13.2.4. Prebiotics/Fibers
- 13.2.5. Others
- 13.3. Market Value Forecast, by Dosage Form, 2017-2031
- 13.3.1. Capsule Form
- 13.3.2. Liquid Form
- 13.3.3. Powder Form
- 13.3.4. Others
- 13.4. Market Value Forecast, by FSMP Mode of Administration, 2017-2031
- 13.4.1. Oral Nutrition (ON)
- 13.4.2. Enteral Nutrition (EN)
- 13.5. Market Value Forecast, by CKD Stage, 2017-2031
- 13.5.1. Pre-dialysis Stage 1-2
- 13.5.2. Pre-dialysis Stage 3-5
- 13.5.3. Dialysis
- 13.5.4. End-stage Renal Disease
- 13.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.6.1. Hospital Pharmacies
- 13.6.2. Retail Pharmacies
- 13.6.3. Online Stores
- 13.7. Market Value Forecast By Country/Sub-region, 2017-2031
- 13.7.1. Germany
- 13.7.2. U.K.
- 13.7.3. France
- 13.7.4. Spain
- 13.7.5. Italy
- 13.7.6. Rest of Europe
- 13.8. Market Attractiveness Analysis
- 13.8.1. By Nutrition Type
- 13.8.2. By Dosage Form
- 13.8.3. By FSMP Mode of Administration
- 13.8.4. By CKD stage
- 13.8.5. By Distribution Channel
- 13.8.6. By Country/Sub-region
14. Asia Pacific Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Nutrition Type, 2017-2031
- 14.2.1. Amino Acid Supplements
- 14.2.1.1. Alpha-Ketoanalogue Supplements
- 14.2.1.2. Alpha Lipoic Acid Supplements
- 14.2.1.3. Others
- 14.2.2. Vitamin & Mineral Supplements
- 14.2.3. Probiotics
- 14.2.4. Prebiotics/Fibers
- 14.2.5. Others
- 14.3. Market Value Forecast, by Dosage Form, 2017-2031
- 14.3.1. Capsule Form
- 14.3.2. Liquid Form
- 14.3.3. Powder Form
- 14.3.4. Others
- 14.4. Market Value Forecast, by FSMP Mode of Administration, 2017-2031
- 14.4.1. Oral Nutrition (ON)
- 14.4.2. Enteral Nutrition (EN)
- 14.5. Market Value Forecast, by CKD Stage, 2017-2031
- 14.5.1. Pre-dialysis Stage 1-2
- 14.5.2. Pre-dialysis Stage 3-5
- 14.5.3. Dialysis
- 14.5.4. End-stage Renal Disease
- 14.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.6.1. Hospital Pharmacies
- 14.6.2. Retail Pharmacies
- 14.6.3. Online Stores
- 14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.7.1. China
- 14.7.2. Japan
- 14.7.3. India
- 14.7.4. Taiwan
- 14.7.5. Australia & New Zealand
- 14.7.6. Rest of Asia Pacific
- 14.8. Market Attractiveness Analysis
- 14.8.1. By Nutrition Type
- 14.8.2. By Dosage Form
- 14.8.3. By FSMP Mode of Administration
- 14.8.4. By CKD stage
- 14.8.5. By Distribution Channel
- 14.8.6. By Country/Sub-region
15. Latin America Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
- 15.1. Introduction
- 15.2. Market Value Forecast, by Nutrition Type, 2017-2031
- 15.2.1. Amino Acid Supplements
- 15.2.1.1. Alpha-Ketoanalogue Supplements
- 15.2.1.2. Alpha Lipoic Acid Supplements
- 15.2.1.3. Others
- 15.2.2. Vitamin & Mineral Supplements
- 15.2.3. Probiotics
- 15.2.4. Prebiotics/Fibers
- 15.2.5. Others
- 15.3. Market Value Forecast, by Dosage Form, 2017-2031
- 15.3.1. Capsule Form
- 15.3.2. Liquid Form
- 15.3.3. Powder Form
- 15.3.4. Others
- 15.4. Market Value Forecast, by FSMP Mode of Administration, 2017-2031
- 15.4.1. Oral Nutrition (ON)
- 15.4.2. Enteral Nutrition (EN)
- 15.5. Market Value Forecast, by CKD Stage, 2017-2031
- 15.5.1. Pre-dialysis Stage 1-2
- 15.5.2. Pre-dialysis Stage 3-5
- 15.5.3. Dialysis
- 15.5.4. End-stage Renal Disease
- 15.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 15.6.1. Hospital Pharmacies
- 15.6.2. Retail Pharmacies
- 15.6.3. Online Stores
- 15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
- 15.8. Market Attractiveness Analysis
- 15.8.1. By Nutrition Type
- 15.8.2. By Dosage Form
- 15.8.3. By FSMP Mode of Administration
- 15.8.4. By CKD stage
- 15.8.5. By Distribution Channel
- 15.8.6. By Country/Sub-region
16. Middle East & Africa Chronic Kidney Disease Nutritional Supplement Market Analysis and Forecast
- 16.1. Introduction
- 16.2. Market Value Forecast, by Nutrition Type, 2017-2031
- 16.2.1. Amino Acid Supplements
- 16.2.1.1. Alpha-Ketoanalogue Supplements
- 16.2.1.2. Alpha Lipoic Acid Supplements
- 16.2.1.3. Others
- 16.2.2. Vitamin & Mineral Supplements
- 16.2.3. Probiotics
- 16.2.4. Prebiotics/Fibers
- 16.2.5. Others
- 16.3. Market Value Forecast, by Dosage Form, 2017-2031
- 16.3.1. Capsule Form
- 16.3.2. Liquid Form
- 16.3.3. Powder Form
- 16.3.4. Others
- 16.4. Market Value Forecast, by FSMP Mode of Administration, 2017-2031
- 16.4.1. Oral Nutrition (ON)
- 16.4.2. Enteral Nutrition (EN)
- 16.5. Market Value Forecast, by CKD Stage, 2017-2031
- 16.5.1. Pre-dialysis Stage 1-2
- 16.5.2. Pre-dialysis Stage 3-5
- 16.5.3. Dialysis
- 16.5.4. End-stage Renal Disease
- 16.6. Market Value Forecast, by Distribution Channel, 2017-2031
- 16.6.1. Hospital Pharmacies
- 16.6.2. Retail Pharmacies
- 16.6.3. Online Stores
- 16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 16.7.1. GCC Countries
- 16.7.2. South Africa
- 16.7.3. Rest of Middle East & Africa
- 16.8. Market Attractiveness Analysis
- 16.8.1. By Nutrition Type
- 16.8.2. By Dosage Form
- 16.8.3. By FSMP Mode of Administration
- 16.8.4. By CKD stage
- 16.8.5. By Distribution Channel
- 16.8.6. By Country/Sub-region
17. Competition Landscape
- 17.1. Market Player - Competition Matrix (by tier and size of companies)
- 17.2. Market Share Analysis/Ranking, by Company, 2021
- 17.3. Company Profiles
- 17.3.1. Abbott Laboratories
- 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.1.2. Product Portfolio
- 17.3.1.3. Financial Overview
- 17.3.1.4. Strategic Overview
- 17.3.1.5. SWOT Analysis
- 17.3.2. Ajanta Pharma Limited
- 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.2.2. Product Portfolio
- 17.3.2.3. Financial Overview
- 17.3.2.4. Strategic Overview
- 17.3.2.5. SWOT Analysis
- 17.3.3. Fresenius Kabi AG
- 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.3.2. Product Portfolio
- 17.3.3.3. Financial Overview
- 17.3.3.4. Strategic Overview
- 17.3.3.5. SWOT Analysis
- 17.3.4. Hexagon Nutrition Limited
- 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.4.2. Product Portfolio
- 17.3.4.3. Financial Overview
- 17.3.4.4. SWOT Analysis
- 17.3.5. Mankind Pharma Ltd.
- 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.5.2. Product Portfolio
- 17.3.5.3. Strategic Overview
- 17.3.5.4. SWOT Analysis
- 17.3.6. Nestle S.A.
- 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.6.2. Product Portfolio
- 17.3.6.3. Financial Overview
- 17.3.6.4. Strategic Overview
- 17.3.6.5. SWOT Analysis
- 17.3.7. Nutricia Limited (Danone S.A.)
- 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.7.2. Product Portfolio
- 17.3.7.3. Financial Overview
- 17.3.7.4. Strategic Overview
- 17.3.7.5. SWOT Analysis
- 17.3.8. PRINE Health MSO, LLC
- 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.8.2. Product Portfolio
- 17.3.8.3. SWOT Analysis
- 17.3.9. RPG Life Sciences Limited
- 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.9.2. Product Portfolio
- 17.3.9.3. Financial Overview
- 17.3.9.4. Strategic Overview
- 17.3.9.5. SWOT Analysis